Pressure BioSciences (OTCQB: PBIO), a global leader in the development and sale of broadly enabling, high-pressure-based equipment, consumable products, and specialty services to the life sciences, nutraceuticals, cosmeceuticals and other industries, is reporting on a consumer focus group. The focus group was designed to test a THC Nanoemulsion Oral Spray designed for rapid, direct absorption through the cheeks and prepared with PBI’s revolutionary Ultra Shear Technology(TM) platform by PBI’s California-based partner companies, including Crème De Canna, a California-licensed manufacturer and long-established provider of innovative, high-quality cannabis products. The focus group showed speedy onset of first effects, much faster progression to maximum effects, the elimination of health issues associated with smoking or vaping and enormous efficiency improvement in dose payload delivery. In addition, the company noted that subsequent consumer focus group testing strongly affirmed these pivotal results. “These extended study results have confirmed the potential for a market transformation in THC consumption with a new oral/transdermal dosing modality in between the existing smoke/vape and edible food/beverage bifurcation of this enormous market,” said Pressure BioSciences president and CEO Richard T. Schumacher in the press release. “We believe that the customer experience with UltraShear processed Nano-THC will be compelling to drive a tidal change in the market, with potential explosive adoption of UltraShear processed Nano-THC. . . . We are experiencing similar reactions and developments as we work with early partners across multiple other markets in nutraceuticals, cosmeceuticals, food/beverage and more. 2023 is poised to be a watershed transformational year for PBI, as we capitalize for roll-out of the UltraShear platform and converge upon our announced NASDAQ or NYSE uplisting goal.”
To view the full press release, visit https://ibn.fm/etJol
About Pressure BioSciences Inc.
Pressure BioSciences is a global leader in providing innovative, broadly enabling, high-pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical and agrochemical, as well as food and beverage manufacturing. The company’s products utilize both constant and alternating pressure. Its patented enabling technology platform — Pressure Cycling Technology (“PCT”) — utilizes alternating cycles of pressure to control biomolecular interactions, such as cell lysis and biomolecule extraction, safely and reproducibly. PCT-based products are beginning to be widely used for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counterbioterrorism applications. PBIO has recently expanded its market opportunities with the acquisition of the BaroFold(TM) patented technology platform, allowing the company to enter the biopharma contract services and GMP manufacturing equipment sector. The company has also developed the scalable and high-efficiency pressure-based UltraShear Technology platform, which allows for the creation of stable nanoemulsions of otherwise immiscible fluids. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room temperature-stable low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. The company’s commitment to innovation and cutting-edge technology has established PBIO as a leader in the high-pressure industry, providing unique and effective solutions to its customers. For more information, visit the company website at www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to SYATF are available in the company’s newsroom at http://ibn.fm/PBIO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork
